Skip to main content
. 2023 Jul 22;24(14):11781. doi: 10.3390/ijms241411781

Figure 2.

Figure 2

The effect of SAS combined with cisplatin or paclitaxel on the viability of OCCC cell lines. TOV21G, RMG-1, HAC-2 and ES-2 cells were treated with (A) 10 µM CDDP and/or 400 µM SAS, and (B) 10 nM paclitaxel and/or 400 µM SAS for 24 h, and the cell viability was assessed using an MTS assay. Cell viability was calculated from the ratio of the absorbance of cells treated to that of the untreated cells (set as 1) (n = 8). Data are presented as the mean ± SD. Different letters above the bars indicate a significant difference (p < 0.05, n = 8, in each group). SAS, sulfasalazine; CDDP, cisplatin; PTX, paclitaxel.